Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS) -- Ignore unavailable to you. Want to Upgrade?

To: William J. Leiby who wrote (551)	2/3/1998 12:23:00 PM
From: Damon Pham	Read Replies (1) \| Respond to of 849

Leading Urology Centers Report Advantages of Matritech NMP22(R) Bladder Cancer Test February Journal of Urology Editorial and Article Identify Value of Non-invasive Test in Patient Management NEWTON, Mass., Feb. 3 /PRNewswire/ -- Leading urologists at the Massachusetts General Hospital, Boston Medical Center and M.D. Anderson Cancer Center reported in the February 1998 issue of The Journal of Urology results of clinical studies in which ''NMP22 offered advantages over cytology in terms of increased sensitivity and reduced cost.'' The NMP22(R) Test Kit, marketed and manufactured by Matritech (Nasdaq: NMPS - news), is the first in a series of innovative cancer detection tests the Company is developing based on Nuclear Matrix Protein (NMP) technology. The study evaluated a total of 231 patients at various stages of disease with a history of transitional cell carcinoma of the bladder. The authors of the study found that the overall sensitivity of NMP22 for high risk tumors was 90%, and that the test was less costly, representing a significant improvement over traditional methods of urinary cytology. The authors of the article also stated: ''We believe that the use of this tumor marker may someday supplant urinary cytology and reduce the frequency of surveillance cystoscopy. ...This report is a promising start to a more favorable outcome in quality of life for bladder cancer patients.'' ''This study highlights NMP22's increased level of sensitivity and underscores its potential to improve the management of patients with bladder cancer,'' said David L. Corbet, President of Matritech. ''Matritech is applying its NMP technology to the development of tests for the management of patients with other major types of cancers, including colon, cervical, breast and prostate.'' Bladder cancer is the fourth most common cancer in men and the eighth most common cancer in women in the United States. Although most new cases of bladder cancer are diagnosed in early stages, the likelihood of recurrence is 50-75% in five years, with most cases reoccurring within the first year. Currently, urinary cytology is routinely used as an adjunct to cystoscopy during follow-up of patients. It is estimated that there are presently over four million urine cytologies performed in the United States every year. Conclusions from this study report that NMP22 offers advantages over cytology including reduced cost and increased sensitivity. An editorial, also published in the February issue of The Journal of Urology, observes that the studies represent an important step towards defining the clinical use of NMP22, and point to the value of urinary tumor markers such as NMP22 as supplemental tests in combination with cytoscopy. Matritech, Inc., based in Newton, MA, is using its proprietary NMP technology, discovered at the Massachusetts Institute of Technology (MIT) and licensed exclusively to Matritech, to develop and commercialize innovative serum-, cell-, and urine-based diagnostics that enable physicians to reliably detect and monitor the presence of bladder, breast, cervical, colorectal and prostate cancers. All of Matritech's diagnostic assays are based the discovery that nuclear matrix proteins in cancer cells differ from those in normal cells. Any forward-looking statements related to the Company's expectations regarding the performance, benefits to patients, market acceptance and future sales of the Company's existing and future products are subject to a number of risks and uncertainties, many of which are beyond the Company's control. These include but are not limited to, risks related to incorrect use of products by customers, unforeseen delays in FDA and other regulatory approvals, future product demand and pricing, performance of distributors, competitive products, and technical developments, health care reform and general business and economic conditions. There can be no assurance that the Company's expectations for its product will be achieved. SOURCE: Matritech Inc.

To: William J. Leiby who wrote (551)	2/4/1998 1:47:00 AM
From: John McCarthy	Read Replies (1) \| Respond to of 849

Hi Bill - Just gotta be up front with you buddy. I'm on Bev's side!!!! No matter what.<g> And Bev - PLEASE - stop acting in such a nice, civil manner. You two folks are alot more fun than this stupid stock. Changing subject .... Bill - betcha a nickel. (No NMPS22 SALES IN 1998) Why? Did you catch the CRAP that came out of the Mass. Hospital. into the Journal of .... God - they must be desperate!!!! (Please publish an article,please etc.) Geeze ... (I'm laughing now) I hope sales are greater than -0-. What cracks me up is that all the *assholes that run this company come from this Hospital. They have lunch with these buzzards. Talk about professional ethics - vomit. Can you picture it. What did they do, run around the hospital offering a sale on NMPS stock? If someone would publish ... anything. If it wasn't so sad, it be embarrasing. Oh well. My 2 cents is .... we live or die by the colon thingie. Regards to both of you. John